James Hermiller
Overview
Explore the profile of James Hermiller including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
2234
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kodali S, Hahn R, Davidson C, Narang A, Greenbaum A, Gleason P, et al.
J Am Coll Cardiol
. 2023 May;
81(18):1766-1776.
PMID: 37137586
Background: Surgical management of isolated tricuspid regurgitation (TR) is associated with high morbidity and mortality, thereby creating a significant need for a lower-risk transcatheter solution. Objectives: The single-arm, multicenter, prospective...
12.
Hibbert B, Zahr F, Simard T, Labinaz M, Nazer B, Sorajja P, et al.
JACC Cardiovasc Interv
. 2023 Mar;
16(11):1369-1380.
PMID: 36989271
Background: Heart failure (HF) is associated with both mortality and a significant decline in health status. Interatrial shunting is increasingly being investigated as a novel therapeutic option. Objectives: The ALT...
13.
McCarthy P, Whisenant B, Asgar A, Ailawadi G, Hermiller J, Williams M, et al.
J Am Heart Assoc
. 2023 Feb;
12(4):e027504.
PMID: 36752231
Background The current standard of care for the treatment of patients with primary mitral regurgitation (MR) is surgical mitral valve repair. Transcatheter edge-to-edge repair with the MitraClip device provides a...
14.
Hausleiter J, Lim D, Gillam L, Zahr F, Chadderdon S, Rassi A, et al.
J Am Coll Cardiol
. 2023 Feb;
81(5):431-442.
PMID: 36725171
Background: Mitral valve transcatheter edge-to-edge repair is safe and effective in treating degenerative mitral regurgitation (DMR) patients at prohibitive surgical risk, but outcomes in complex mitral valve anatomy patients vary....
15.
Lakkireddy D, Thaler D, Ellis C, Swarup V, Sondergaard L, Carroll J, et al.
Heart Rhythm O2
. 2022 Nov;
3(5):493-500.
PMID: 36340489
Background: Left atrial appendage (LAA) occlusion is an alternative therapy to oral anticoagulants to reduce stroke risk in patients with nonvalvular atrial fibrillation (NVAF). The Amulet IDE trial compared the...
16.
Inanc I, Cilingiroglu M, Iliescu C, Ninios V, Matar F, Ates I, et al.
Cardiovasc Revasc Med
. 2022 Oct;
47:76-85.
PMID: 36270966
This review compares the recommendations of the recent 2020 American College of Cardiology (ACC)/American Heart Association (AHA) and 2021 European Society of Cardiology (ESC)/European Association for Cardio-Thoracic Surgery (EACTS) guidelines...
17.
Lim D, Smith R, Gillam L, Zahr F, Chadderdon S, Makkar R, et al.
JACC Cardiovasc Interv
. 2022 Sep;
15(24):2523-2536.
PMID: 36121247
Background: Severe symptomatic degenerative mitral regurgitation (DMR) has a poor prognosis in the absence of treatment, and new transcatheter options are emerging. Objectives: The CLASP IID (Edwards PASCAL Transcatheter Valve...
18.
Valgimigli M, Cao D, Angiolillo D, Bangalore S, Bhatt D, Ge J, et al.
J Am Coll Cardiol
. 2021 Nov;
78(21):2060-2072.
PMID: 34794687
Background: The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) among patients at high bleeding risk (HBR) is unknown. Objectives: The purpose of this analysis was...
19.
Mehran R, Cao D, Angiolillo D, Bangalore S, Bhatt D, Ge J, et al.
JACC Cardiovasc Interv
. 2021 Sep;
14(17):1870-1883.
PMID: 34503737
Objectives: The aim of this study was to evaluate 2 abbreviated dual-antiplatelet therapy (DAPT) regimens in patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI). Background: Current-generation drug-eluting...
20.
Lakkireddy D, Thaler D, Ellis C, Swarup V, Sondergaard L, Carroll J, et al.
Circulation
. 2021 Aug;
144(19):1543-1552.
PMID: 34459659
Background: Percutaneous closure of the left atrial appendage (LAA) is an alternative to chronic oral anticoagulation to reduce stroke risk in patients with nonvalvular atrial fibrillation. The Amulet IDE trial...